Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 20, 2003, Pages 2693-2702

  Rosenheck, Robert ^a,b   Perlick, Deborah ^a,b   Bingham, Stephen ^c   Liu Mares, Wen ^a,b   Collins, Joseph ^c   Warren, Stuart ^d   Leslie, Douglas ^a,b   Allan, Edward ^f   Campbell, E Cabrina ^f   Caroff, Stanley ^f   Corwin, June ^f   Davis, Lori ^f   Douyon, Richard ^g   Dunn, Lawrence ^h   Evans, Denise ^f   Frecska, Ede ⁱ   Grabowski, John ^f   Graeber, David ^e   Herz, Lawrence ^f   Kwon, Kong ^f   Lawson, William ^j   Mena, Felicitas ^f   Sheikh, Javaid ^k   Smelson, David ^f   Smith Gamble, Valerie ^l   more..

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d University of New Mexico   (United States)

^e VA Medical Center   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h DURHAM VA MEDICAL CENTER   (United States)

ⁱ Bay Pines VA Medical Center   (United States)

^j HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^l RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; HALOPERIDOL; OLANZAPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; MEMORY; MENTAL DISEASE; MOTOR PERFORMANCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SCHIZOPHRENIA; STANDARDIZATION; STATISTICAL ANALYSIS; UNITED STATES; WEIGHT GAIN;

EID: 0345293130     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.20.2693     Document Type: Article

References (62)

1. Bromet EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GE, eds. Textbook in Psychiatric Epidemiology. New York, NY: John Wiley & Sons; 1996.
2. Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, eds. Handbook of Mental Health Economics and Health Policy, Volume 1: Schizophrenia. New York, NY: John Wiley & Sons; 1996.
3. Kerwin RW. The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994;164:141-148.
4. Geddes J, Freemantle N, Harrison P, Bebbington P, for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta regression analysis. BMJ. 2000;321:1371-1376.
5. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev [serial online]. 2002;2: CD001359.
6. Rosenheck RA, Leslie DL, Sernyak ME. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care. 2001;39:302-308.
7. Jewell M. Zyprexa takes over Prozac's reign at Eli Lilly. Available at: http://www.courier-journal.com /business/news2003/O4/22/biz-3-lil22-6905.html. Accessed April 25, 2003.
8. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
9. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-137.
10. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
11. Revicki LA, Genduso LA, Hamilton SH, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: quality of life outcomes of a randomized clinical trial. Qual Life Res. 1999;8:417-426.
12. Hamilton SH, Edgell ET, Revicki LA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol. 2000;15:245-255.
13. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia-results from a randomised clinical trial. Pharmacoeconomics. 1999;15:469-480.
14. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155:914-920.
15. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology. 1998;18:41-49.
16. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry. 2001;62 (suppl 7):4-10.
17. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl 23):30-38.
18. Sernyak MJ, Leslie D, Alarcon R, Losonczy M, Rosenheck RA. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
19. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
20. Meyer J. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
21. Rosenheck RA, Cramer J, Xu W, et al, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809-815.
22. Essock SM, Frisman LK, Covell NH, Hargreaves W. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals. Arch Gen Psychiatry. 2000;57:987-994.
23. First MB, Spitzer RL, Gibbon MB, Williams JB. Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). New York, NY: Biometrics Research Institute, New York State Psychiatric Institute; 1996.
24. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
25. Rosenheck R, Tekall J, Peters J, et al. Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry. 1998;55:618-625.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
27. Cramer JA, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull. 2001;27:227-235.
28. Heinrichs DW, Hanlon ET, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
29. Barnes TR. A rating scale for drug induced akathisia. Br J Psychiatry. 1989;154:672-676.
30. Guy W, Abnormal involuntary movements. In: Guy W, ed. ECDEU Assessment Manual for Psychopharamcology. Rockville, Md: National Institute of Mental Health; 1976.
31. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
32. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Dept of Health, Education, and Welfare; 1976:217-222. Publication ADM 76-338.
33. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, Mass: Health Institute, New England Medical Center; 1993.
34. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status. Odessa, Fla: Psychological Assessment Resources Inc; 1997.
35. Reitan RM. Manual for the Administration of Neuropsychological Test Batteries for Adults and Children. Tucson, Ariz: Neuropsychology Press; 1979.
36. Heaton RK. A Manual for the Wisconsin Card Sorting Test. Odessa, Fla: Psychological Assessment Resources Inc; 1981.
37. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City: Department of Neurology, University of Iowa Hospitals; 1978.
38. Jastak S, Wilkinson GS. Wide Range Achievement Test-Revised: Administration Manual. Wilmington, Del: Jastak Assoc; 1984.
39. Barnett PG. Review of methods to determine VA health care costs. Med Care. 1999;37(suppl VA):AS9-AS17.
40. Wagner TH, Chen S, Yu W, Branett PG. HERCs Inpatient Average Cost Data Sets for VA Care: Fiscal Years 1998 and 1999. Palo Alto, Calif: Health Economics Resource Center; 2001.
41. Neale M, Rosenheck R, Baldino R, Cavallaro L. Intensive Psychiatric Community Care (IPCC) in the Department of Veterans Affairs: Second National Performance Monitoring Report. West Haven, Conn: Northeast Program Evaluation Center; 1999.
42. Leslie D, Rosenheck RA. Shifting to outpatient care? mental health utilization and costs in a privately insured population. Am J Psychiatry. 1999;156:1250-1257.
43. Kasprow WJ, Rosenheck RA, Chapdelaine J, Carter R. Health Care for Homeless Veterans Programs: Twelfth Progress Report. West Haven, Conn: Northeast Program Evaluation Center; 1999.
44. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001;286:1715-1723.
45. Dewan M. Are psychiatrists cost-effective? an analysis of integrated versus split treatment. Am J Psychiatry. 1999;156:324-326.
46. Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 1999.
47. Frisman LK, Rosenheck RA. How transfer payments are treated in cost-effectiveness and cost-benefit analysis. Adm Policy Ment Health. 1996;23:533-546.
48. Schobel BD. Administrative expenses under OASDI. Soc Secur Bull. 1981;44:21-28.
49. US Department of Justice. Office of Justice Programs, Bureau of Justice Statistics. Justice Expenditures and Employment in the United States; 1988. Washington, DC: US Government Printing Office; 1991.
50. US Department of Justice. Statistics Maguire K, Flanagan T, eds. Sourcebook of Criminal Justice Statistics - 1990 (NCJ-130580). Washington, DC: US Government Printing Office; 1991.
51. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry. 1993;50:739-750.
52. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
53. Kane JM, Schizophrenia, N Engl J Med. 1996;334:34-41.
54. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry. 2002;159:1035-1043.
55. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40:1113-1117.
56. Klein DF, Davis JM. Diagnosis and Treatment of Psychiatric Disorders. Baltimore, Md: Williams & Wilkins; 1969:165.
57. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of current evidence. Harv Rev Psychiatry. 2002;10:280-291.
58. Rosenheck RA, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull. 2003;29:81-93.
59. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
60. Rosenheck R, Cramer J, Xu W, et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Health Serv Res. 1998;33:1237-1261.
61. Rosenheck RA, Kasprow W, Frismn LK, Liu-Mates W. Cost-effectiveness of supported housing for homeless persons with mental illness. Arch Gen Psychiatry. 2003;60:940-951.
62. Pyne JM, Sullivan G, Kaplan R, Williams DK. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care. 2003;41:208-217.